All Press Releases
July 14, 2025
Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer
June 2, 2025
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
May 19, 2025
Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model
May 7, 2025
Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria
February 10, 2025
Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 10, 2025
Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
November 14, 2024
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis
August 5, 2024
Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
May 17, 2024
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting
April 23, 2024
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray
October 31, 2023
Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit
October 17, 2023
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
August 30, 2023
Recludix Pharma to Participate in Multiple Investor Conferences in September
July 20, 2023
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
March 7, 2023
Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
February 1, 2023
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
January 6, 2023
Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
October 20, 2022
Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology
September 29, 2022